Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
- PMID: 18952677
- DOI: 10.1093/brain/awn235
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
Abstract
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease patients and represents a major limitation for the pharmacological management of the motor symptoms in advanced disease stages. We have recently demonstrated that dopamine released from serotonin neurons is responsible for l-DOPA-induced dyskinesia in 6-hydroxydopamine (6-OHDA)-lesioned rats, raising the possibility that blockade of serotonin neuron activity by combination of 5-HT(1A) and 5-HT(1B) agonists could reduce l-DOPA-induced dyskinesia. In the present study, we have investigated the efficacy of 5-HT(1A) and 5-HT(1B) agonists to counteract l-DOPA-induced dyskinesia in 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP)-treated macaques, the gold standard model of Parkinson's disease. In addition, we have studied the ability of this treatment to prevent development of l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. The results demonstrate the existence of a potent synergistic effect between 5-HT(1A) and 5-HT(1B) agonists in their ability to dampen l-DOPA-induced dyskinesia in the MPTP-treated macaques. Sub-threshold doses of the drugs, which individually produced no effect, were able to reduce the abnormal involuntary movements by up to 80% when administered in combination, without affecting the anti-parkinsonian properties of l-DOPA. Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model. Our results support the importance of a clinical investigation of the effect of 5-HT(1A) and 5-HT(1B) agonists, particularly in combination, in dyskinetic l-DOPA-treated Parkinson's disease patients.
Similar articles
-
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.Neurobiol Aging. 2010 Jun;31(6):926-36. doi: 10.1016/j.neurobiolaging.2008.06.017. Epub 2008 Aug 15. Neurobiol Aging. 2010. PMID: 18707801
-
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.Brain. 2007 Jul;130(Pt 7):1819-33. doi: 10.1093/brain/awm082. Epub 2007 Apr 23. Brain. 2007. PMID: 17452372
-
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.Parkinsonism Relat Disord. 2009 Jul;15(6):445-52. doi: 10.1016/j.parkreldis.2008.11.001. Epub 2009 Feb 3. Parkinsonism Relat Disord. 2009. PMID: 19196540
-
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Prog Brain Res. 2008. PMID: 18772047 Review.
-
Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.Mov Disord. 2008;23 Suppl 3:S585-98. doi: 10.1002/mds.22022. Mov Disord. 2008. PMID: 18781676 Review.
Cited by
-
Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia.Cells. 2023 Mar 8;12(6):837. doi: 10.3390/cells12060837. Cells. 2023. PMID: 36980178 Free PMC article.
-
SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias.EJNMMI Res. 2013 Jun 5;3(1):44. doi: 10.1186/2191-219X-3-44. EJNMMI Res. 2013. PMID: 23738774 Free PMC article.
-
Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease.Parkinsons Dis. 2012;2012:370190. doi: 10.1155/2012/370190. Epub 2012 Jun 11. Parkinsons Dis. 2012. PMID: 22762012 Free PMC article.
-
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence.Front Pharmacol. 2022 Apr 7;13:805388. doi: 10.3389/fphar.2022.805388. eCollection 2022. Front Pharmacol. 2022. PMID: 35462934 Free PMC article. Review.
-
Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model.IBRO Rep. 2018 Dec 14;6:40-44. doi: 10.1016/j.ibror.2018.12.001. eCollection 2019 Jun. IBRO Rep. 2018. PMID: 30656239 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous